

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): June 28, 2021

**Natus Medical Incorporated**  
(Exact name of registrant as specified in its charter)

000-33001  
(Commission File Number)

Delaware  
(State or other jurisdiction  
of Incorporation)

77-0154833  
(I.R.S. Employer  
Identification No.)

6701 Koll Center Parkway, Suite 120  
Pleasanton, CA 94566  
(Address of principal executive offices) (Zip Code)

925-223-6700  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	NTUS	The Nasdaq Stock Market LLC (The Nasdaq Global Market)

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On June 28, 2021, Dr. Barbara R. Paul, chairperson of the Board of Directors (the "Board") of Natus Medical Incorporated (the "Company"), informed the Board that she will retire, both as chairperson of the Board and as a director on the Board, effective as of the end of the day on June 30, 2021. Dr. Paul's decision to retire as chairperson of the Board and as a director on the Board did not result from any disagreement with the Company or its management. The Board elected Joshua H. Levine, who is presently a director on the Board, as chairperson of the Board effective as of the end of the day on June 30, 2021.

**Item 7.01. Regulation FD Disclosure.**

On June 28, 2021, the Company issued a press release announcing Dr. Paul's retirement. A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
<a href="#">99.1</a> 104	<a href="#">Press release dated June 28, 2021.</a> The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101).

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NATUS MEDICAL INCORPORATED**  
*(Registrant)*

Dated: June 28, 2021

By: /s/ B. Drew Davies  
Executive Vice President and Chief Financial Officer



## **Natus Chairperson Dr. Barbara Paul Retires; Board Elects Current Board Member Joshua Levine as Chairperson**

**PLEASANTON, Calif. (June 28, 2021) - Natus Medical Incorporated** (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced Dr. Barbara Paul, the Chairperson of the Board of Directors will retire from the Board effective June 30, 2021. The Board has elected independent director Joshua Levine who has served on the Natus board since 2018 as the new Chairperson.

Jonathan Kennedy, President and Chief Executive Officer of Natus, said, “Barbara played an instrumental role on our board over the past five years, helping to guide the One Natus transformation. Barbara’s experience as a healthcare provider has proven to be valuable to all our stakeholders and we are a stronger company as a result of her contributions. Barbara’s guidance and counsel will be missed, and I am grateful for her service.”

“I have appreciated and enjoyed the opportunity to serve on Natus’ board, and am proud of the collective achievements and significant progress made by the Company over the past five years. It has been my privilege to serve as board chair,” said Dr. Paul.

“I am grateful for the trust of my fellow board members in appointing me to this leadership position. I want to thank Dr. Paul for her service and leadership of the board,” said Joshua Levine, Natus’ new Chairperson of the Board of Directors.

Dr. Paul’s decision to retire from the Board after five years of distinguished service did not result from any disagreement with the Company or its management

### **About Natus Medical Incorporated**

Natus is a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Additional information about Natus Medical can be found at [www.natus.com](http://www.natus.com).

Natus Medical Incorporated  
B. Drew Davies  
Executive Vice President and Chief Financial Officer  
(925) 223-6700  
[InvestorRelations@Natus.com](mailto:InvestorRelations@Natus.com)